文献速递炎症性肠病

古塞奇尤单抗治疗克罗恩病:2期GALAXI-1研究诱导治疗结果

Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
PubMed 文献 · Gastroenterology · 2022-02-05

GALAXI-1是一项2期双盲安慰剂对照研究,309例中重度活动性克罗恩病患者按1:1:1:1:1随机接受静脉古塞奇尤单抗200mg、600mg或1200mg(第0、4、8周)、静脉乌司奴单抗约6mg/kg(第0周)及第8周皮下90mg或安慰剂。第12周时,三个古塞奇尤单抗组克罗恩病活动指数较基线下降及临床缓解率均显著优于安慰剂,安全性事件率总体相似。

要点

  • 第12周时古塞奇尤单抗200mg、600mg、1200mg组CDAI较基线下降均显著大于安慰剂。
  • 第12周临床缓解率古塞奇尤单抗各组均显著高于安慰剂(16.4%)。
  • 古塞奇尤单抗各组临床应答、PRO-2缓解、临床-生物标志物应答及内镜应答比例均高于安慰剂。

核心结论

  • 第12周时,古塞奇尤单抗全部3种剂量方案诱导的临床和内镜改善均大于安慰剂,安全性特征良好。

研究设计与样本

  • GALAXI-1为2期双盲安慰剂对照研究,309例中重度活动性克罗恩病患者按1:1:1:1:1随机分组。
  • 古塞奇尤单抗组分别静脉给予200mg、600mg或1200mg,于第0、4、8周给药。
  • 乌司奴单抗为参照组:第0周静脉约6mg/kg,第8周皮下90mg。
  • 评估至第12周,主要终点为克罗恩病活动指数较基线变化。

主要发现

  • 第12周CDAI较基线最小二乘均值变化:古塞奇尤单抗200mg组-160.4、600mg组-138.9、1200mg组-144.9 vs 安慰剂组-36.2,所有P < .05。
  • 第12周临床缓解(CDAI <150)率:古塞奇尤单抗200mg组57.4%、600mg组55.6%、1200mg组45.9% vs 安慰剂组16.4%,所有P < .05。
  • 古塞奇尤单抗组第12周临床应答、PRO-2缓解、临床-生物标志物应答及内镜应答比例均高于安慰剂组。
  • 乌司奴单抗 vs 安慰剂的疗效亦得到证实。
  • 安全性事件率在各治疗组间总体相似。

关键数值与推荐

  • 主要终点为第12周克罗恩病活动指数较基线变化。
  • 主要次要终点包括临床缓解、临床应答、PRO-2缓解、临床-生物标志物应答及内镜应答。
  • 临床缓解定义为CDAI <150。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Guselkumab, a selective p19 interleukin-23 antagonist, is approved for the treatment of plaque psoriasis and psoriatic arthritis. This study evaluated the efficacy and safety of guselkumab in patients with moderately to severely active Crohn's disease with inadequate response or intolerance to conventional or biologic therapy. METHODS: GALAXI-1, a phase 2, double-blind, placebo-controlled study, randomized patients 1:1:1:1:1 to intravenous guselkumab 200 mg, 600 mg, or 1200 mg at weeks 0, 4, and 8; intravenous ustekinumab approximately 6 mg/kg at week 0 and 90 mg subcutaneously at week 8; or placebo. Change from baseline in Crohn's Disease Activity Index score (primary end point), clinical remission, clinical response, Patient Reported Outcomes-2 remission, clinical-biomarker response, endoscopic response (major secondary end points), and safety in guselkumab-treated patients vs placebo were evaluated through week 12. Ustekinumab was a reference arm. RESULTS: Of 309 patients evaluated, approximately 50% had disease refractory to prior biologic therapy. At week 12, significantly greater reductions in Crohn's Disease Activity Index from baseline (least squares means: 200 mg: -160.4, 600 mg: -138.9, and 1200 mg: -144.9 vs placebo: -36.2; all, P < .05) and significantly greater proportions of patients achieved clinical remission in each guselkumab group vs placebo (Crohn's Disease Activity Index <150; 57.4%, 55.6%, and 45.9% vs 16.4%; all, P < .05). Greater proportions of patients receiving guselkumab achieved clinical response, Patient Reported Outcomes-2 remission, clinical-biomarker response, and endoscopic response at week 12 vs placebo. Efficacy of ustekinumab vs placebo was also demonstrated. Safety event rates were generally similar across treatment groups. CONCLUSIONS: At week 12, all 3 dose regimens of guselkumab induced greater clinical and endoscopic improvements vs placebo, with a favorable safety profile. CLINICALTRIALS: gov, Number: NCT03466411.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Sandborn WJ, D'Haens GR, Reinisch W, et al. Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology. 2022. PMID: 35134323. doi:10.1053/j.gastro.2022.01.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。